Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports best-ever full year performance for FY24 Strides declares a final dividend of Rs. 2.5 per share22-05-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports best-ever full year performance for FY24 Strides declares a final dividend of Rs. 2.5 per shareStrides Pharma Science Ltd - 532531 - Corporate Action-Board approves Dividend
Recommendation of Final Dividend for FY ended March 31, 2024Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - May 22, 2024
Outcome of Board Meeting - May 22, 2024Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10mLStrides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation pursuant to Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - Rajagopalan JStrides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of audited financial results for the quarter and year ended March 31, 2024Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 ,inter alia, to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing RegulationsStrides Pharma Science's shares rise 1.64% on USFDA approval
Strides Pharma Science's subsidiary Strides Pharma Global Pte Limited received USFDA's approval for Sevelamer Carbonate TabletsStrides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800mgStrides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issuance of LOC - Priti D Sangani